Hormones growth inhibiting

Somatostatin [38916-34-6] M 1637.9, [a]p -36 (c 0.57, 1% AcOH). A tetradecapeptide which is purified by gel filtration on Sephadex G-25, eluting with 2N AcOH, and then by liquid partition chromatography on Sepahdex G-25 using n-BuOH-AcOH-H20 (4 1 5) and has Rp= 0.4. It is a brain growth hormone releasing-inhibiting factor which has also been synthesised. [Burgus et al. Proc Natl Acad Sci USA 70 684 1973, Sorantakis and McKinley Biochem Biophys Res Commun 54 234 1973 Hartridt et al. Pharmazie 37 403 1982.]... 

Somatostatin SOM SST14 SST28 Somatotropin release inhibitory factor (SRIF) Growth hormone release-inhibiting factor... 

Somatostatin is a regulatory cyclic peptide, which has originally been described as a hypothalamic growth hormone release-inhibiting factor. It is produced throughout the central nervous system (CNS) as well as in secretoty cells of the periphery and mediates its regulatory functions on cellular processes such as neurotransmission, smooth muscle contraction, secretion and cell proliferation via a family of seven transmembrane domain G-protein-coupled receptors termed sstx 5. 

Growth Hormone Release-inhibiting Factor GSK3... 

Somatostatin Growth hormone-release inhibiting factor (8,9) (51110-01-1)... 

The advantages of recombinant DNA technology are enormous, as the following example shows. Somatostatin is a hormone that inhibits the secretion of pituitary growth hormone. The researchers who first isolated somatostatin required nearly half a million sheep brairrs to produce 5 mg of the substance. Using a chemically synthesized gene, 9... 

The mRNA expression of PEPT1 varies significantly in response to several chemical factors. The expression of the transporter was upregulated by substrates [89, 90], diet [91, 92], insulin [93], a2-adrenergic agonists [93], and pentazocine [94]. While it has been reported that intestinal transplantation [89, 95], cAMP [96], epidermal growth factor [97], and thyroid hormone [98] inhibited the expression of PEPT1. 

Nickel ions have been shown to depress the in vivo and in vitro release of prolactin [336], while the release of growth hormone was stimulated, and only at relatively high ion concentrations. Hyperglycemia occurs in rats following intraperitoneal or intratracheal injections of NiCl2 [265, 337, 338], The mechanism of action of nickel appears to be inhibition of insulin release this inhibition could be related to the extremely high concentration of nickel found in the pituitary and the effect on the secretion of the pituitary hormones (growth hormone and adrenocorticotropic hormone). 

Hypothalamic hormone Human growth hormonereleasing hormone and -inhibiting hormone (somatostatin)... 

---